Clinical Trial Update: Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 study evaluating anti-CD19 iCAR NK cells for relapsed and refractory B-cell lymphoma. The current sponsor-reported status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Anti-CD19 iCAR NK Cells (CD19-targeted iCAR NK cell therapy)

Snippet

Sponsor: Allife Medical Science and Technology Co., Ltd. | Conditions: Refractory B-Cell Lymphoma | EARLY_Phase 1 | Status: UNKNOWN